nitial €50,000 Phase 1 grant will fund full feasibility study

Symcel: Symcel, the company behind the revolutionary cell-based assay tool for real-time cellular bioenergetic measurements,calScreener™, has secured Horizon 2020 Phase I funding to prepare the company for the planned commercialisation of its groundbreaking technology. The €50,000 Phase 1 grant will fund a full feasibility study.

calScreener, the calorimetry based diagnostic tool, addresses the industry’s inability to carry out anti microbial susceptibility testing in key clinical fields, including biofilm infection, due to the non existence to date of effective assay and monitoring technologies available to the market. Symcel’s novel technology and approach meets these unmet diagnostic needs head on. It provides clinicians dealing with bacterial infections with accurate and fast tests that determine whether an antibiotic should be used in the patient, the type of antibiotic to utilize and the choice of therapy